Back to the Top
Dear Forum,
We would like to explore the pharmacokinetics of our recombinant
protein based vaccine. We intend to measure the protein levels in the
serum by ELISA following single IM injection. Analyzing the serum
should reduce the background in the assay. However, I know that
plasma is normally used for this purpose. Is there any harm in
employing serum rather than plasma? Are we missing something in
allowing the blood coagulation while preparing the serum?
Best regards,
Avi Gordon
Regulatory and Clinical Affairs Manager
BiondVax Pharmaceuticals Ltd.
Science Park, Building No. 14,
Rehovot 76326, Israel
Telephone: +972-8-9302529
Mobile: +972-54-8058155
gordon.-a-.biondvax.com
www.BiondVax.com
Back to the Top
Dear Avi Gordon,
IMO, serum is mostly common used for ELISA analysis. I have done some
PK of recombinant proteins. As far as I know, either plasma or serum
is fine with the ELISA kit if you buy from the commercial producer.
So if you get a better result with serum, then go ahead. I not not
think it will lose anything.
Best regards,
Hu
Back to the Top
The following message was posted to: PharmPK
Avi,
It may be okay to use plasma if the drug being analyzed does not
interact with the coagulation factors. At the same time, the drug
should not interact with anti-coagulants in the plasma tube. You
also save time with plasma since you do not have to let the blood
stand to clot to obtain serum.
Thanks
Ananda
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)